Goldman Sachs Ninth Annual European Private Company Forum

May 18, 2017

London, Great Britain
Participant: Peter Willinger, CFO



May 22 - 23, 2017

Paris, France
Paricpant: Peter Willinger, CFO

UBS - Globals Healthcare Conference

May 22 - 24, 2017

New York, USA
Participant: Thomas Hoeger, PhD, CEO
 May 23, 2017, 3:30 pm: "Apogenix - Next Generation Immuno-Oncology Therapeutics"


Sachs 3rd Annual Immuno-Oncology: BD&L and Investment Forum

June 2, 2017

Chicago, USA
Participant: Juergen Gamer, PhD, VP Business Development
June 2, 2017, 10:20 am: Pannel "New Approaches to IO & Combination Therapies"


ASCO Annual Meeting

June 2 - 6,  2017

Chicago, USA
Participants: Harald Fricke, PhD, CMO/COO
Claudia Kunz, PhD, Director Clinical Development


2nd EACR-AACR-SIC Special Conference:
The Challenges of Optimising Immuno and Targeted Therapies

June 24 - 27, 2017

Florence, Italy
Participants:  Meinolf Thiemann, PhD, Director Assay Development
June 25, 2017, poster presentation: "Hexavalent CD27 agonists show single agent anti-tumor activity in mouse
syngeneic tumor models which is augmented by combination with anti-PD-1"